Denali Therapeutics Inc. Stock

$14.58

2.86% today

Nasdaq, Jul 16, 06:46 pm CET

ISIN

US24823R1059

Symbol

DNLI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Denali Therapeutics Inc. Stock price

$14.17

-12.84 47.54% 5Y

Nasdaq, Closing price Tue, Jul 15 2025

-0.52 3.54%

ISIN

US24823R1059

Symbol

DNLI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$2.1b

Enterprise Value

$1.2b

Net debt

positive

Cash

$817.9m

Shares outstanding

145.3m

Valuation (TTM | estimate)

P/E

- | negative

P/S

- | 89.4

EV/Sales

- | 54.1

EV/FCF

negative

P/B

1.8

Financial Health

Equity Ratio

89.5%

Return on Equity

-34.4%

ROCE

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

- | $23.0m

EBITDA

- | $-537.3m

EBIT

- | $-571.4m

Net Income

- | $-447.7m

Free Cash Flow

$-384.4m

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

Get Started for Free Today

Denali Therapeutics Inc. Stock Analysis

Unlock Scores for Free

??

25 Analysts have issued a Denali Therapeutics Inc. forecast:

24x Buy

96%

More details on Analyst Estimates Including Price Targets

25 Analysts have issued a Denali Therapeutics Inc. forecast:

Buy

96%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Denali Therapeutics Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	105 105	2% 2% -
- Research and Development Expense	396 396	6% 6% -
EBITDA	-493 -493	174% 174% -
- Depreciation and Amortization	8.99 8.99	46% 46% -
EBIT (Operating Income) EBIT	-502 -502	155% 155% -
Net Profit	-423 -423	191% 191% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Denali Therapeutics Inc. Stock News

Neutral

GlobeNewsWire

●

9 days ago

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approval Tividenofusp alfa is designed to deliver missing enzyme to entire body and cross blood-brain barrier into the brain Tividenofusp alfa leads company's broader TransportVehicle™-enabled pipeline SOUTH SAN FRANCISCO, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today a...

Neutral

GlobeNewsWire

●

2 months ago

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided business highlights.

Neutral

GlobeNewsWire

●

4 months ago

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

SOUTH SAN FRANCISCO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the company's initiation of a rolling submission of a biologics license application (BLA) for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome (MPS II) has been received by the Center for Drug Evaluation and Research (CDER) of the U.S. Food ...

More Denali Therapeutics Inc. News

Company Profile

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Head office	United States
CEO	Ryan Watts
Employees	422
Founded	2013
Website	www.denalitherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now